Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Liabilities and Shareholders Equity (2016 - 2026)

Kamada's (KMDA) quarterly Liabilities and Shareholders Equity came in at $383.2 million in Q2 2026, up 4.07% on a YoY basis from $368.2 million in Q2 2025, and little changed quarter-over-quarter from $383.0 million in Q1 2026.

Analysis

Kamada (KMDA) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends

Kamada (KMDA) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $383.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Liabilities and Shareholders Equity rose 4.07% year-over-year to $383.2 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 3.77% YoY), and the FY2025 full-year result was $378.7 million, up 1.73% from the prior year.
  • Liabilities and Shareholders Equity steadied at $383.2 million in Q2 2026 per KMDA's latest filing, from $383.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $383.2 million in Q2 2026 and bottomed at $303.1 million in Q1 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $347.5 million across 5 years, with a median of $351.1 million in 2024.
  • The widest YoY moves for Liabilities and Shareholders Equity: up 47.62% in 2022, down 1.16% in 2022.
  • Over 5 years, Liabilities and Shareholders Equity stood at $322.4 million in 2022, then advanced by 10.09% to $354.9 million in 2023, then gained by 4.89% to $372.3 million in 2024, then gained by 1.73% to $378.7 million in 2025, then advanced by 1.18% to $383.2 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $383.2 million, $383.0 million, and $378.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Amgen 211.30 Bn 197.31 Bn 7.24 Bn 95.64 Bn
2 Gilead Sciences 180.97 Bn 177.79 Bn 6.22 Bn 49.36 Bn
3 Vertex Pharmaceuticals 132.27 Bn 124.42 Bn 2.84 Bn 27.42 Bn
4 Regeneron Pharmaceuticals 82.93 Bn 74.93 Bn 3.93 Bn 41.73 Bn
5 Argenx Se 61.53 Bn 56.35 Bn 1.37 Bn 10.03 Bn
6 Moderna 54.27 Bn 49.13 Bn 52.00 Mn 10.96 Bn
7 Alnylam Pharmaceuticals 34.46 Bn 31.15 Bn 992.69 Mn 5.56 Bn
8 Biogen 31.16 Bn 29.88 Bn 1.96 Bn 32.09 Bn
9 Roivant Sciences 30.08 Bn 30.08 Bn 1.16 Mn 5.31 Bn
10 Kamada 473.85 Mn 403.72 Mn 22.47 Mn 383.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 383.16 Mn
Mar 31, 2026 383.02 Mn
Dec 31, 2025 378.71 Mn
Sep 30, 2025 377.21 Mn
Jun 30, 2025 368.17 Mn
Mar 31, 2025 375.11 Mn
Dec 31, 2024 372.26 Mn
Sep 30, 2024 351.21 Mn
Jun 30, 2024 351.04 Mn
Mar 31, 2024 343.17 Mn
Dec 31, 2023 354.91 Mn
Sep 30, 2023 337.06 Mn
Jun 30, 2023 314.39 Mn
Mar 31, 2023 316.80 Mn
Dec 31, 2022 322.38 Mn
Sep 30, 2022 319.64 Mn
Jun 30, 2022 304.14 Mn
Mar 31, 2022 303.10 Mn
Dec 31, 2021 318.67 Mn
Sep 30, 2021 216.53 Mn